Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Alhemo. Always confirm against the full prescribing information.
4 interactions
Antihemophilic factor, human recombinant
The risk or severity of thromboembolism can be increased when Antihemophilic factor, human recombinant is combined with Concizumab.
Level 1 evidence
Coagulation Factor IX (Recombinant)
The risk or severity of thromboembolism can be increased when Coagulation Factor IX (Recombinant) is combined with Concizumab.
Level 1 evidence
Coagulation factor VIIa Recombinant Human
The risk or severity of thromboembolism can be increased when Coagulation factor VIIa Recombinant Human is combined with Concizumab.
Level 1 evidence
Factor IX Complex (Human)
The risk or severity of thromboembolism can be increased when Factor IX Complex (Human) is combined with Concizumab.
Alhemo (Concizumab) has 4 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Alhemo (Concizumab) has 0 major, 4 moderate, and 0 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Alhemo. Always confirm against the full prescribing information.